Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 05 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as unable to get materials from GE, study not proceeding and never opened to accrual
- 05 Sep 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018.
- 20 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2022.